{"filings":[{"id":2576801,"accession_number":"0001477932-26-005329","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2026-08-31T20:05:33+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Creative Medical shareholders approve share increase to 100M and full warrant exercise","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized shares increased from 25M to 100M via Certificate of Amendment filed in Nevada on Aug 28, 2026.","Share increase proposal passed with 2,488,537 for, 595,527 against, 14,822 abstain.","Warrant exercise proposal for 5,580,680 shares passed: 678,541 for, 344,460 against, 1,092,794 broker non-votes.","Warrants originated from June 30, 2026 private placement; quorum was 3,098,886 shares (65.4% outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1415360,"accession_number":"0001477932-26-004165","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2026-07-02T20:15:27+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Creative Medical raises ~$4.5M via warrant exercise inducement; issues new warrants for 5.58M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrants for 2.79M shares exercised at reduced price of $1.60/share, raising ~$4.5M gross proceeds.","In exchange, company issued new inducement warrants to purchase 5.58M shares at $1.60, exercisable after stockholder approval.","Net proceeds to be used for working capital and general corporate purposes.","CEO Timothy Warbington awarded $100,000 bonus approved by Compensation Committee on July 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118314,"accession_number":"0001477932-25-009277","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders approve exercise of warrants for 2.79M shares of Creative Medical Technology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrants to purchase 2,790,340 shares issued Oct 29, 2025, approved at Dec 26 special meeting.","Vote: 618,178 For, 183,985 Against, 235,381 Abstain (220,500 For votes reclassified as Abstain per Nasdaq rules).","Quorum of 36.4% of outstanding shares was present at the special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118313,"accession_number":"0001477932-25-009094","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"All five director nominees elected at 2025 annual meeting; say-on-pay and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five director nominees elected: For votes 419,951–434,837; withhold votes under 57,000 each.","Say-on-pay compensation approved: 335,623 For, 108,092 Against, 32,561 Abstain, 1,113,524 broker non-votes.","Ratification of Haynie & Company as auditor approved: 1,346,871 For, 115,979 Against, 126,950 Abstain.","Quorum of 1,589,800 shares (61.5% of outstanding) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118312,"accession_number":"0001477932-25-008027","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Creative Medical Technology Holdings approves $100k CEO and $25k CFO bonuses","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee approved bonuses on November 6, 2025","CEO Timothy Warbington receives $100,000 bonus","CFO Donald Dickerson receives $25,000 bonus","Bonuses disclosed in Item 5.02 of Form 8-K filed November 12, 2025"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118311,"accession_number":"0001477932-25-007849","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CELZ raises ~$4.2M via warrant exercise inducement; issues 2.79M new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of 1,116,136 warrants exercised at $3.75/share, yielding $4.2M gross proceeds.","Company issued 2,790,340 new inducement warrants at $3.75/share, exercisable 5 years after shareholder approval.","Roth Capital received 8% fee plus $40,000 expense reimbursement for acting as financial advisor.","Proceeds to be used for working capital and general corporate purposes.","Exercise price of certain 2021/2022 warrants reduced to $4.73 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151666,"accession_number":"0001477932-25-003370","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Stockholders approve exercise of warrants for 1.8M shares at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on May 5, 2025; 35% quorum (813,562 shares) present.","Proposal to exercise warrants on 1,799,774 shares approved: 308,051 For, 39,229 Against, 466,282 Abstain.","Warrants were issued March 6, 2025; approval allows immediate exercise.","No broker non-votes reported; warrants represent ~78% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151665,"accession_number":"0001477932-25-002645","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Creative Medical receives Nasdaq notice for late clawback policy adoption; matter closed as now compliant.","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On April 8, 2025, Nasdaq notified Creative Medical for failure to timely adopt and disclose Clawback Policy per Listing Rule 5608.","Company adopted policy on April 4, 2025 with retroactive effect to Dec 1, 2023; no incentive compensation affected.","Nasdaq confirmed company currently in compliance and matter is closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170515,"accession_number":"0001477932-25-001737","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Creative Medical Tech awards $100k in bonuses to CEO and CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Timothy Warbington received a $70,000 bonus approved March 10, 2025.","CFO Donald Dickerson received a $30,000 bonus on the same date.","Bonuses were approved by the Compensation Committee of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170514,"accession_number":"0001477932-25-001537","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Creative Medical Technology raises $3.7M via warrant exercise inducement; issues new warrants at $3.75","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.7M from cash exercise of 837,104 existing warrants at $4.42/share.","Issued new inducement warrants to purchase 1,674,208 shares at $3.75, 5-year term, exercisable after stockholder approval.","New warrants unregistered; company to file resale registration on Form S-3 within 30 days.","Roth Capital receives 8% fee plus warrants for 5% of shares underlying exercised and new warrants.","Proceeds will be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187508,"accession_number":"0001477932-24-008314","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Shareholders vote to increase authorized shares from 5M to 25M, approve warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 5M to 25M via Certificate of Amendment filed Dec 19, 2024.","Shareholders approved exercise of warrants for 837,104 shares issued in Oct 23, 2024 private placement.","Series A and B Preferred Stock certificates withdrawn; no shares outstanding at time.","Proposal I passed with over 64M combined votes for vs 35M against (including preferred stock auto-vote).","Proposal II passed with 301,878 for, 105,960 against, 420,793 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187507,"accession_number":"0001477932-24-006644","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CELZ raises $1.85M in registered direct offering of shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$1.85M; net ~$1.6M after fees and expenses; proceeds for working capital.","Offering of 418,552 shares at $4.42; warrants for up to 837,104 shares at $4.42.","Warrants exercisable after stockholder approval, five-year term; closed Oct 23, 2024.","Roth Capital Partners served as exclusive placement agent; offering under effective S-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204003,"accession_number":"0001477932-24-004377","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Creative Medical Technology Holds 2024 Annual Meeting; Say-on-Pay Vote Fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five director nominees elected; Timothy Warbington and others received >300K votes for vs ~147K withhold.","Say-on-pay vote: 217,019 for, 227,926 against, 15,317 abstain, with 371,908 broker non-votes; not approved.","Ratification of Haynie & Company as auditor passed with 684,717 for, 90,973 against, 56,480 abstain.","Proposal to increase authorized shares was withdrawn by management before the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220688,"accession_number":"0001477932-24-003116","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","5.08","9.01"],"status":"ready","headline":"CEO buys one Series B Preferred share with special voting rights on share increase; annual meeting July 19","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Timothy Warbington purchased one Series B Preferred share for $100; it carries 100M votes on share increase proposal.","Series B Preferred votes proportionally with common stock on proposal to increase authorized common from 5M to 25M shares.","Series B automatically redeemed upon approval of share increase; not convertible into common.","Annual meeting of stockholders set for July 19, 2024; record date June 3, 2024.","Preliminary proxy statement filed with SEC regarding share increase and other proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257811,"accession_number":"0001477932-23-009261","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders elect all five director nominees and approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 55.9% (776,982 shares) present at December 20, 2023 annual meeting.","All five director nominees elected with 234,462 to 237,729 votes in favor; no dissent above 26,758.","Say-on-pay approved: 169,498 for, 90,645 against, 1,077 abstain, 515,762 broker non-votes.","Ratification of auditor Haynie & Company approved: 751,848 for, 23,485 against, 1,649 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292585,"accession_number":"0001477932-23-004849","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Creative Medical regains Nasdaq minimum bid price compliance after 10-day stretch above $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 27, 2023 that it regained compliance with Listing Rule 5550(a)(2).","Closing bid price exceeded $1.00 for 10 consecutive trading days (June 12–26, 2023).","Previously notified of non-compliance on July 8, 2022; now compliant with all listing standards.","CEO states company has sufficient funds to meet operating costs and capex through 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292584,"accession_number":"0001477932-23-004441","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Creative Medical Technology announces 1-for-10 reverse stock split effective June 12, 2023 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-10; outstanding shares reduced from ~14.1M to ~1.4M.","Authorized shares cut from 50M to 5M; no change to par value of $0.001.","Effective 9:00 a.m. ET on June 12, 2023 under ticker CELZ; new CUSIP 22529Y408.","Fractional shares rounded up to whole share; no cash paid in lieu.","Action intended to bring stock above $1.00 minimum bid price for Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331770,"accession_number":"0001477932-22-009401","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Creative Medical Technology shareholders elect all directors, approve executive compensation and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven directors elected with votes ranging from 2,675,852 to 2,694,252 in favor; no withhold above 361,796.","Executive compensation approved with 2,422,079 for, 588,661 against, 26,908 abstain, 4,818,286 broker non-votes.","Advisory vote on executive compensation set to every one year, approved with 2,854,354 for one year.","Ratification of Haynie & Company as auditor approved with 7,690,484 for, 144,871 against, 20,579 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349251,"accession_number":"0001477932-22-005098","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2022-07-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Creative Medical receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice for non-compliance with Listing Rule 5550(a)(2) due to bid price below $1.00 for 30 consecutive days.","180-day grace period until January 4, 2023 to regain compliance by closing at $1.00+ for 10 consecutive business days.","Company may be eligible for additional 180-day grace period if it meets Nasdaq Capital Market initial listing standards.","Management to monitor bid price and consider available options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366144,"accession_number":"0001477932-22-002951","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Creative Medical raises $17M in PIPE with shares, pre-funded & common warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$17M from sale of 2,991,669 shares, pre-funded warrants for 4,563,887 shares, and common warrants for 15,111,112 shares at $2.25/unit.","Common warrants have 5-year term, exercise price $2.00; pre-funded warrants have $0.0001 exercise price, no expiration.","Placement agent Roth Capital received $1.36M cash fee and warrant for 1,133,333 shares with same terms as common warrants.","Directors and officers agreed to 90-day lock-up from earliest of registration effective date or Rule 144 sale.","Company committed to file resale registration statement for all shares and warrant shares issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366143,"accession_number":"0001477932-22-002950","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Creative Medical raises ~$17M in private placement with institutional investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company sold 2,991,669 shares, 4,563,887 pre-funded warrants ($0.0001 exercise), and 15,111,112 common warrants ($2.00; 5-year term) at $2.25 per combined unit.","Gross proceeds of approximately $17 million; net after placement agent fees of $1.36 million and warrants to Roth for 1,133,333 shares.","Directors and officers signed 90-day lock-up agreements triggered by registration effectiveness or Rule 144 eligibility.","Company agreed to file registration statement covering resale of shares and warrant shares under Registration Rights Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385630,"accession_number":"0001477932-22-000691","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2022-02-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Creative Medical enters new 3-year employment agreements with CEO and CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Warbington base salary $330,000/year; CFO Dickerson $300,000/year.","Each eligible for annual cash bonus targeted at 30% of base salary.","Annual option grant valued at 30% of base salary, vesting over 3 years (25% immediate, then annual).","Severance: if terminated without cause or for good reason, 2 years of base salary plus bonuses.","Employment agreements have 3-year initial term with automatic renewal for successive 3-year periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403523,"accession_number":"0001477932-21-009015","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2021-12-07T23:59:59+00:00","items":["1.01","3.01","5.02","9.01"],"status":"ready","headline":"Creative Medical Technology Holdings prices $16M public offering, uplists to Nasdaq, appoints new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 3.875M shares and warrants at $4.13 per combined unit; gross proceeds ~$16M.","Common stock begins trading on Nasdaq Capital Market under ticker CELZ as of Dec 3, 2021.","Thomas Ichim and Amit Patel resigned as directors; Michael Finger, Susan Snow, Bruce Urdang appointed.","Proceeds to redeem $5.1M in senior notes, repurchase ~$195k of Series A preferred from CEO, fund clinical trials.","Underwriter Roth Capital granted 45-day option for up to 581,250 additional shares/warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403522,"accession_number":"0001477932-21-007944","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Creative Medical announces 1-for-500 reverse stock split; authorized shares cut to 50M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1:500 effective Nov 10, 2021; outstanding shares reduced from ~1.23B to ~2.45M.","Authorized shares reduced from 25B to 50M via Certificate of Change filed Nov 8, 2021.","Temporary ticker changes to CELZD for up to 20 business days or until Nasdaq listing.","Split intended to meet Nasdaq minimum bid price requirement for planned uplisting from OTC.","No fractional shares; any fractional interest rounded up to one whole share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403521,"accession_number":"0001477932-21-007874","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2021-11-05T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Creative Medical increases authorized common shares from 6B to 25B; withdraws Series B and C Preferred designations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 6,000,000,000 to 25,000,000,000 via Certificate of Amendment filed Nov 2, 2021.","Certificates of Withdrawal filed for Series B and Series C Convertible Preferred Stock; no shares outstanding at time of filing.","Prior exchanges of preferred stock for Bridge Notes (August 2021) left no outstanding shares of those series."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422482,"accession_number":"0001477932-21-006554","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2021-09-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Creative Medical enters direct employment with CEO, CFO, consultants; ends reimbursement agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Timothy Warbington receives $330k annual base salary effective 9/16/2021.","CFO Donald Dickerson receives $300k annual base salary effective 9/16/2021.","Consultants Dr. Thomas Ichim and Dr. Amit Patel receive $120k and $240k per annum respectively.","Prior Management Reimbursement Agreement with Creative Medical Health terminated 9/15/2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422481,"accession_number":"0001477932-21-005384","cik":1187953,"company_name":"CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.","ticker":"CELZ","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Creative Medical raises ~$3.8M via 15% OID senior notes and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Sold $4,456,176 principal amount of 15% OID senior notes for $3,787,750 in cash.","Notes mature Feb. 11, 2022; no interest except on default; not convertible.","Issued warrants to purchase 157,184,354 common shares at $0.02835/share, 5-year term.","Roth Capital received $312,750 placement fee and a warrant for 10,094,408 shares.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8502336.32034632,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}